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Pulmonary hypertension (PH) is a rare disease, whose underlying mechanisms are not 
fully understood. It is characterized by pulmonary arterial vasoconstriction and vessels 
wall thickening, mainly intimal and medial layers. Several molecular pathways have been 
studied, but their respective roles remain unknown. Cardiac repercussions of PH are 
hypertrophy, dilation, and progressive right ventricular dysfunction. Multiple echocardio-
graphic parameters are being used, in order to assess anatomy and cardiac function, 
but there are no guidelines edited about their usefulness. Thus, it is now recommended 
to associate the best-known parameters, such as atrial and ventricular diameters or 
tricuspid annular plane systolic excursion. Cardiac catheterization remains necessary to 
establish the diagnosis of PH and to assess pulmonary hemodynamic state. Concerning 
energetic metabolism, free fatty acids, normally used to provide energy for myocardial 
contraction, are replaced by glucose uptake. These abnormalities are illustrated by 
increased 18F-fluorodeoxyglucose (18F-FDG) uptake on positron emission tomography/
computed tomography, which seems to be correlated with echocardiographic and 
hemodynamic parameters.
Keywords: pulmonary hypertension, right ventricle, PeT/CT, echocardiography, cardiac catheterization
iNTRODUCTiON
Pulmonary hypertension (PH) is a serious disease, which evolves progressively to cardiac insuf-
ficiency and death (1, 2). It is characterized by increased pressures and resistances in pulmonary 
arteries. The diagnosis is made, by cardiac catheterization, by a mean pulmonary arterial pressure 
(PAPm) ≥25 mmHg. We talk about pulmonary arterial hypertension (PAH) when the pulmonary 
wedge pressure (PWP) is ≤15 mmHg and pulmonary vascular resistance (PVR) >3 WU (3, 4). We 
can classify the etiologies of PH in five different groups, according to DanaPoint classification (2008) 
and maintained with minor modifications after the fifth World symposium in Nice (2013), with 
the first group related to etiologies leading to PH of arterial origin and sharing similar histological 
pattern. All groups of PH are characterized by similar symptoms, especially dyspnea, cough, angina, 
fainting, or peripheral edemas (4, 5).
Without treatment, survival does not exceed 2–3 years with chronic PAH. Moreover, the diag-
nosis is usually made when cardiac repercussions and clinical symptoms are already severe [75% of 
patients in New York Heart Association (NYHA) class III or IV] (1, 5). Thus, it is necessary to develop 
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new tools to make earlier diagnosis and to increase knowledge in 
medical caregivers about this poorly known disease.
The aim of this article is to review current knowledge about 
pathophysiology and cardiac repercussions of PAH, as well as 
the different clinical, biological, and imagery parameters used to 
assess PAH and right heart function.
CLASSiFiCATiON OF PULMONARY 
HYPeRTeNSiON
Etiologies and forms of PH are classified in five groups, accord-
ing Dana Point classification (2008). Different forms of PAH 
are joined in Group 1, to know idiopathic PAH, heritable PAH, 
PAH related to drugs and toxins, connective tissue disease, 
HIV, schistosomiasis, portal hypertension, and congenital heart 
 disease. As previously mentioned, PWP is <15 mmHg, and PVR 
is >3 WU. Treatments for PAH are described below. Second 
group is PH related to left heart disease. Echocardiography and 
cardiac catheterization show left ventricular dysfunction. PWP is 
>15 mmHg, and PVR is >3 WU. These forms are mainly treated 
with usual treatments of left ventricular dysfunction or repair 
valvular diseases. If these are not sufficient, specific treatments 
for PH, such as vasodilators, can be added. Third group contains 
PH forms related to lung disease, such as chronic obstructive 
pulmonary disease, interstitial diseases, or sleep apneas. They are 
characterized by a PWP <15 mmHg and pathological pulmonary 
functional tests. First line treatment is an optimal therapy of 
the underlying disease and long-term oxygen therapy. Fourth 
group is chronic thromboembolic PH. As in PAH, PAPm is 
>25 mmHg, and PWP is <15 mmHg. Multiple thrombi can be 
found by pulmonary computed tomography or magnetic reso-
nance angiography or by pulmonary ventilation/perfusion scan. 
Chronic thromboembolic PH can be reversed by endarterectomy, 
and long-term anticoagulation is recommended. In inoperable 
patients, or if PH persists after surgery, treatments of PAH can 
be useful. Last group contains PH forms from multifactorial and 
unclear mechanisms, such as hematologic diseases, sarcoidosis, 
or metabolic disease. PWP is a variable (3). After the fifth sym-
posium in Nice (2013), minor modifications have been done. In 
Group 1, a few more mutations are described. Persistent PH of 
the newborn has been separated from other causes of PAH and 
some congenital cardiopathies have been added to Group 2 (4). 
The aim of this article is to review pathogenesis and evaluation 
of PAH forms.
PATHOBiOLOGY AND THeRAPeUTiC 
TReATMeNT OPTiONS
Histology
Multiple abnormalities are found in histological analysis of 
lungs from PAH patients, mostly in small arteries. They all 
induce thickening of vessels wall. The first step in this process is 
thickening of intima, by increased proliferation and migration of 
local stem cells. Medial and adventitial layers are also altered, by 
medial smooth muscle cells hypertrophy, which invade the wall of 
small arteries, usually not muscularized, and by accumulation of 
fibroblasts from the adventitia. Extracellular matrix is produced 
and degraded in excess by metalloproteinases, which releases 
mitogenic factors for smooth muscle cells. Eventually, adventi-
tial mesenchymatous cells called myofibroblasts migrate to the 
media and induce proliferation of smooth muscle cells. Later in 
the obstructive vascular process, hypertrophy and hyperplasia of 
endothelial cells, also known as neointima formation, continue 
and form plexiform lesions. Plexiform lesions are a monoclonal 
proliferation of endothelial cells forming multiple channels into 
one obliterated arteriole, surrounded by smooth muscle cells, 
extracellular matrix, and myofibroblastes (Figure  1). Beyond 
morphological abnormalities, they present many functional and 
metabolic alterations (6–8). As in many other proliferative dis-
eases, several growth factors, such as vascular endothelial growth 
factor (VEGF), platelet-derived growth factor (PDGF), or epider-
mal growth factor (EGF), are involved in vessels wall hyperplasia, 
through tyrosine kinase activation. Their overexpression in 
endothelial cells promotes inflammation, proliferation, migra-
tion, and survival of smooth muscle cells and fibroblasts. Greater 
serotonin sensitivity and increased transporter’s expression were 
found in smooth muscle cells, and a greater amount of serotonin, 
through its mitogenic effects, could take part to thickening of vas-
cular wall (6, 7, 9, 10). The trigger for these changes in unknown, 
but some studies hypothesized that an endothelial injury could 
promote this proliferation. Indeed, Sakao et  al. showed that 
inhibition of VEGF receptors and mechanical stress can provoke 
endothelial lesions by apoptosis. After a few days, resistance 
against apoptosis appears in surviving cells, probably induced 
by release of mediators from previously injured cells. Resistant 
cells express survivin, an apoptosis inhibitor frequently met in 
malignant tumors (11, 12). Parallel to hyperplasia of vessels wall, 
multiple microthromboses are frequently found in small arteries 
of PH lungs. Three components promote thromboses: activation 
of intravascular coagulation, platelets dysfunction, and release of 
vasoconstrictor and pro-coagulant mediators by endothelial cells. 
Platelets dysfunction and dysfunctional endothelium promote 
intravascular coagulation by releasing plasmatic pro-coagulants 
(von Willebrand factor, thromboxane, and serotonin) and anti-
fibrinolytic molecules (plasminogen activator inhibitor). Platelets 
also store vasoconstrictor and mitotic substances. However, it is 
unclear if microthromboses are a consequence or a trigger for 
elevated PVRs and pressures (7–9).
endothelial Dysfunction
Many studies identified the nitric oxide (NO) pathway to be linked 
to the emergence of PAH. NO is produced by NO synthase (eNOS) 
in endothelial cells. It is the predominant factor inducing vasodi-
lation in normal conditions, via cyclic guanosine monophosphate 
(cGMP). It also inhibits proliferation of smooth muscle cells, 
platelets aggregation and activation, leukocytes migration, and 
endothelin (ET) secretion (9, 12). In mice, an inhibiting mutation 
of eNOS induces increased pulmonary arterial pressure (PAP) 
(13). In humans, it seems that a reduced amount of NO is also 
involved in pathogenesis of PAH, by increased degradation 
and reduced eNOS expression in pulmonary tissues (Figure 1). 
Giaid and Saleh showed a negative correlation between eNOS 
FiGURe 1 | evolution of anatomical and functional abnormalities in 
small arterioles in PAH. (A) Normal vessel: vasodilation is predominant, by 
NO and PGI. (B) Hypertrophy and hyperplasia of endothelial cells, mediated 
by growth factors. (C) Hypertrophy and hyperplasia of smooth muscle cells 
and fibroblasts. Extravasation of inflammatory cells. Endothelial dysfunction 
and clots formation. (D) Plexiform lesions.
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expression in immunohistochemical analysis, severity of vascular 
lesions and PVR (14).
Pathogenesis of PAH can be partly explained by increased ET 
secretion. ET is a neuropeptide released by vascular endothelium. 
It can bind, on vascular wall, to type A receptors, leading to 
vasoconstriction, or type B receptors, leading to vasodilation. 
In pathological conditions, vasoconstrictor effect is predominant 
and takes part to PAH development. ET seems to be acting partly 
by inhibition of Kv1.5 potassium channels synthesis. Increased 
potassium rate in cells induces depolarization and calcium influx 
through voltage-dependant calcium channels. Increased intracel-
lular calcium and potassium rates promote vasoconstriction, pro-
liferation, and apoptosis resistance. ET is thus responsible of both 
hyperplasia and endothelial dysfunction (Figure 1) (9, 10, 15).
Prostaglandins (PGI) pathway could also play a role in PAH 
development. PGI are derived from arachidonic acid and inhibit 
cellular proliferation, inflammation, coagulation, platelets aggre-
gation, and vasoconstriction. A reduced rate is found in PAH 
patients (Figure 1) (7, 9, 12, 16).
This endothelial dysfunction is the target of current PAH treat-
ments, such as ET receptors antagonists, PGI derivates, phospho-
diesterases inhibitors, calcium-channel blockers, or cGMP kinase 
activators. However, it seems that remodeling and occlusion of 
small arteries contributes primarily to the increase of PAP and 
right atrial pressure (RAP). Thus, the therapeutic response is 
highly variable, frequently insufficient, and these treatments can-
not reverse the underlying histological abnormalities (3, 8, 9, 15).
inflammation and immunity
Several studies identified an inflammatory component in patho-
genesis of PAH. Indeed, different types of inflammatory cells 
are found on the surface and into the vessels wall. Furthermore, 
several cytokines and chemokines are excessively produced, by 
inflammatory and endothelial cells, and also take part to smooth 
muscle cells proliferation. Soon et  al. demonstrated that blood 
levels of some cytokines, such as interleukin (IL)-2, IL-6, IL-8, 
or IL-10, could be correlated with survival, which support their 
implication in pathogenesis of PH. For many years, the presence 
of autoantibodies has been discovered in PH related to connec-
tive tissue disease and systemic sclerosis. Recent studies have 
also brought them out in idiopathic PAH cases. Indeed, immu-
noglobulin G (IgG) not only against endothelial cells components 
but also against fibroblasts and smooth muscle cells is found in 
about 60% of patients. Although little is known about the role of 
those antibodies, they could cause endothelial injuries and then 
trigger the excessive proliferation process (6, 10, 17–19).
BMPR2 and TGF-β
Mutations of bone morphogenetic protein receptor type II 
(BMPR2), a kinase receptor from transforming growth factor-
beta (TGF-β) family, are not only found in 70% of patients with 
heritable PH but also in about 25% of patients with idiopathic 
PAH. BMPR2 is usually expressed in pulmonary endothelial cells 
and regulates cell growth, differentiation, and apoptosis, through 
a factor named Smad. Some studies showed that inactivation 
of BMPR2 promotes endothelial cell survival, proliferation, 
angiogenesis, and migration. A loss of BMPR2 could be one of the 
bases of PAH pathogenesis, leading to endothelial injuries, apop-
tosis resistance, and plexiform lesions. It could also be involved 
in remodeling and dysfunction of the right ventricle (RV). 
However, prevalence of PAH in patients with BMPR2 mutation 
is low, which suggests that those mutations remain predisposing 
factors and that other vascular injuries are necessary to develop 
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the disease (6, 9, 20). Abnormalities of other members of TGF-β 
family, such as TGF-β1, which induce proliferation and remod-
eling of vascular wall, seem to be present. Thus, there could be an 
imbalance between BMPR2 and TGF-β1, in favor of an excessive 
proliferation (16, 20).
Survivin
Those different pathways have a common consequence: excessive 
proliferation and apoptosis resistance. As mentioned previously, 
survivin is involved in some proliferative diseases. McMurtry 
et  al. showed that its expression is increased not only in pul-
monary vascular wall, mainly in smooth muscle cells, but also 
in endothelium and fibroblasts. Survivin inhibits apoptosis and 
opening of Kv1.5 potassium channels. In rats, survivin inactivat-
ing treatments are useful to reduce wall remodeling, PAP, and 
RV hypertrophy. It seems that survivin expression can occur after 
endothelial injuries, which is consistent with results obtained 
about the signaling pathways presented above. This factor could 
be one of the links between those pathways and vascular wall 
remodeling (15).
micro-RNAs
Recent studies in rats showed that another link between these 
pathways could be related to micro-ribonucleid acids (miRNAs). 
miRNAs are a family of non-coding RNAs, which regulate expres-
sion of coding RNAs through binging and cleavage in the cyto-
plasm. Different mechanisms, such as hypoxia, hypoxia-inducible 
factor-1alpha (HIF-1α), inflammation, and growth factors, regu-
late miRNAs. It seems that the expression of miRNAs could be 
dysregulated in PAH, as some are increased and others decreased. 
We can mention the example of miR-204, which regulates cellular 
proliferation and apoptosis through B-cell lymphoma-2 (Bcl-2) 
and nuclear factor of activated T-cells (NFAT). This one seems 
to be decreased in smooth muscle cells. ET and PDGF could be 
involved in inhibition of miR-204 (21). Other miRNAs are prob-
ably involved in PH and right heart dysfunction (22, 23).
HiF-1α and Metabolism
Several studies demonstrated that endothelial cells and myocardial 
energetic metabolism is altered. Free fatty acids oxidation, used as 
energetic resource in normal conditions, is replaced by anaerobic 
glycolysis. Molecular analysis of endothelial and myocardial cells 
showed that this metabolic shift is based on normoxic activation 
of the transcription factor HIF-1α (24–26). This factor is normally 
activated in hypoxic conditions, in order to produce energy without 
oxygen, by anaerobic glycolysis. HIF-1α slows down Krebs cycle. 
Free fatty acids oxidation is thus replaced by aerobic or anaerobic 
glycolysis. The latter is predominant, explaining increased lactate 
production, which is observed in PAH. This is called Warburg 
effect and is found in several pathologies, especially in malignant 
tumors (24–28). This results in decreased energy production per 
glucose molecule and, thus increased glucidic needs. Adequate 
intake is provided by increased expression of glucose transporter 
1 (GLUT-1) channels and hexokinase, which are found in greater 
amount, particularly in pulmonary vessels with plexiform lesions 
(24, 25). In rats and in humans, Bonnet et al. showed that all those 
elements reduce cellular metabolic dependence to oxygen and 
give an advantage in hypoxic conditions for cellular proliferation 
and survival. This process depends on the inhibition of Kv1.5 
potassium channels by HIF-1α. The resulting cellular depolariza-
tion induces calcium inflow. Elevated intracellular potassium 
and calcium rates promote proliferation and apoptosis resistance 
(29). In pulmonary vessels, parallel to this metabolic shift, the 
reduced NO production observed in PAH leads to a decreased 
number of mitochondria per cell and inhibits mitochondrial 
genes expression. Mitochondrial function abnormalities are 
also found, specifically in PAH lungs. This results in a reduced 
production of reactive oxygen species and a decreased amount 
of superoxide dismutase (SOD). Hydrogen peroxide production 
(H2O2), normally responsible of HIF-1α inhibition, is inhibited. 
These signaling alterations by reactive oxygen species could be 
the basis of normoxic activation of HIF-1α (24, 26, 28, 29). In the 
myocardium, inhibition of aerobic metabolism probably takes 
part to development hypertrophy, in which a greater expression of 
GLUT-1 channels, decreased oxygen consumption and increased 
lactate production by anaerobic glycolysis are found. This could 
lead to reduced energetic reserves and further reduce right 
heart function (24, 26, 30). Experimental studies investigated 
the efficacy of treatments targeted on this metabolic shift, such 
as imatinib or dichloroactetate. They demonstrated beneficial 
effects on pulmonary remodeling, inflammation, and myocardial 
hypertrophy (24, 25, 27). Feasibility and usefulness of these treat-
ments in humans remain to be determined.
Conclusion
In conclusion, several mechanisms have been proposed to explain 
the abnormal pulmonary vasoconstriction and hyperplasia, but 
links between these different pathways remain unclear. Current 
treatments are not always effective and cannot reverse the histo-
logical abnormalities. Experimental studies are looking for new 
therapeutic targets, in order to inhibit proliferation, reactivate 
apoptosis, and recover a normal organization in pulmonary 
vascular wall.
RiGHT veNTRiCULAR 
PHYSiOPATHOLOGY
Hypertrophy and Dilation
In normal conditions, the RV is a complex structure with three 
different compartments: the filling chamber with the tricuspid 
valve, the apical chamber with the right ventricular free wall, and 
the outflow tract, near from the pulmonary valve. These three 
chambers play a different role in blood ejection toward the pulmo-
nary artery (31). In PAH, the RV loses its contraction delay, which 
is necessary for blood diffusion through the ventricle toward the 
pulmonary artery. All the ventricular structure is altered, and the 
three-chambered structure evolves to a more cylindrical shape, 
which allows blood ejection despite simultaneous contraction of 
all compartments. Those contraction disturbances of ventricular 
wall can be explained by abnormalities of myocardial contractility, 
secondary to an alteration of muscular fibers orientation (31, 32).
In normal conditions, Kind et al. observed that the interven-
tricular septum is made of oblique- and helical-shaped fibers, 
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leading to a twisting contraction. In contrary, right ventricular 
free wall is mostly made of transverse fibers, leading to a circum-
ferential contraction. In PAH, septal fibers orientation becomes 
transverse, which promotes a circumferential contraction, 
observed in the right ventricular remodeling (33).
When the afterload increases because of PAP elevation, RV 
hypertrophy maintains a normal RV ejection fraction (RVEF) 
and diminishes wall stress (34, 35). However, even if this 
mechanism first preserves cardiac function, it leads to diastolic 
dysfunction, ischemia, and dilation of the RV and is, further-
more, not sufficient to preserve cardiac function. Indeed, after 
pressure overload occurring in the beginning of PAH, a volume 
overload appears, probably secondary to tricuspid regurgitation, 
although all mechanisms are not well known yet. This dilation is 
mainly responsible of dysfunction of the RV (36–38). According 
to Archer et  al., we can still differentiate two different pheno-
types, depending on cardiac adaptation to pressure elevation: the 
adaptive phenotype, where the RV is less dilated and fibrotic, the 
RVEF is preserved and remodeling is concentric, and the mala-
daptive phenotype, where the RV is dilated, fibrotic, hypokinetic, 
and remodeling is eccentric (24). Little is known about the 
mechanisms leading to one or the other phenotype, but adap-
tive phenotype is rather observed in children with Eisenmenger 
syndrome, while maladaptive phenotype is seen in other types 
of PAH. There is also probably a continuum between these two 
patterns, as the elevated PAP becomes greater and perpetual 
(34). Indeed, studies showed a good correlation between cardiac 
remodeling and function, and pulmonary vascular abnormali-
ties and hypertrophy. This has led to the conception of RV and 
pulmonary circulation as a unit, where one component cannot 
be considered alone, in order to get a better comprehension of 
their pathophysiology and relations (39–41).
Histology
It is well known that, following exposition to elevated PAP, the 
RV becomes hypertrophic. Histological examination of PAH 
hearts has demonstrated that the myocytes diameter is increased, 
in comparison with normal hearts. It seems that increased right 
ventricular mass is also secondary to cytoplasmic proteins and 
sarcomeres production (41, 42). Moreover, it has been demon-
strated that the passive tension of sarcomeres is increased, by 
reduced phosphorylation of titin, which usually regulates tension 
of sarcomeres. This induces an impaired relaxation of myocytes. 
In parallel, deposition of collagen in the extracellular matrix 
induces fibrosis of the myocardium. Both impaired relaxation 
of myocytes and collagen deposition increase rigidity of the RV 
and induce a diastolic insufficiency, which could participate to 
the right ventricular dysfunction (37). Even if the myocardium 
has limited regenerative and proliferative properties, it seems 
that hyperplasia, by proliferation of progenitor cells, add to 
hypertrophy. After hypertrophy has occurred, these changes of 
structure and function of myocytes, followed by increased apop-
tosis, seem finally to lead to contractile dysfunction and dilation 
of the RV (38, 41, 42). Pathways determining those changes are 
not well known yet. However, it seems that they are probably 
triggered and maintained by inflammation, by neutrophils and 
ILs, oxidative stress, systemic and local neurohormonal factors, 
and ischemia (38, 42, 43). Despite many structural abnormalities 
happen, it seems that these modifications are, at least partially 
reversible, as it is well known that cardiac function improves after 
lungs transplantation or endarterectomy (42).
In the myocardium, alterations of energetic metabolism, 
similar to pulmonary vessels, participate to right ventricular 
hypertrophy and dysfunction. They lead to decreased oxygen 
consumption, increased lactate production, and reduced ener-
getic reserves. Increased GLUT-1 channels and HIF-1α activation 
are found in PAH myocardium and seem to be associated with 
greater right ventricular dysfunction (24, 26, 30).
Septum and Left ventricle
Interventricular septum acts like a passive membrane during 
diastole and systole, whose position depends on blood volume 
and pressure in the left ventricle (LV) and the RV. In PAH, when 
the right ventricular pressure becomes greater than the left ven-
tricular pressure, septum is moved leftward, according to pressure 
gradient. We talk about abnormal eccentricity when the septum 
is moved leftward during systole (44, 45). The septum plays an 
important role in both ventricular contraction and even more in 
the RV in PAH. Indeed, according to López-Candales, it seems 
to be the “ventricular motor” in the right ventricular contraction 
against elevated afterload, which means that it provides most of 
the strength needed for blood ejection. Septal deviation is thus 
involved in progression of right ventricular dysfunction (45).
Right heart dysfunction, by several mechanisms, can also lead 
to a left cardiac dysfunction, related to interdependence of both 
ventricles. Septal abnormal eccentricity, as previously described, 
induces an abnormal left ventricular morphology. Furthermore, 
as the pericardium is not much extensible, the hypertrophied RV 
can compress the LV and diminish its volume. This results in left 
cardiac dysfunction, characterized by a reduced left ventricular 
filling, responsible for a diminished ejection volume (34, 45).
Finally, in PAH, we can find a dyssynchrony between both 
ventricles: right ventricular free wall is still contracting when the 
diastole has begun in the LV, which accentuates septal deviation 
and shortens diastole in the RV. Thus, filling is also reduced in 
the RV (32, 34, 46).
Blood Flow
Cardiac perfusion has been mostly studied in left cardiac hyper-
trophy. In the left coronary artery, in normal conditions, blood 
flow depends on arterial pressure, or aortic pressure, myocardial 
capillary pressure, determined by several neurohumoral and 
metabolic factors, and left ventricular pressure (47). In normal 
conditions, blood flow in the right coronary artery does not 
depend on ventricular contraction. It is a monophasic flow, which 
means that systolic flow is equal to diastolic flow. In contrary, in 
PAH, van Wolferen et al. demonstrated that the right coronary 
blood flow was diminished during systole, and increased dur-
ing diastole. First, blood flow becomes biphasic, as seen in the 
left coronary artery in normal conditions, and thus depends on 
contraction and right ventricular systolic pressure (48). Second, 
the systolic coronary blood flow per mass unit decreases parallel 
to the progression of right ventricular hypertrophy, because of 
microvascular rarefaction compared to ventricular mass and by 
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vessels compression during systole. This can explain the presence 
of sub-endocardial ischemia in severe right ventricular hypertro-
phy, as it is found in left ventricular hypertrophy (24, 38).
CLiNiCAL PARAMeTeRS
Cardiopulmonary exercise Test
Cardiopulmonary exercise test (CPET) has been widely used to 
assess exercise capacity in PAH patients. The patient undergoes 
ergometry with defined initial load, which is progressively 
increased until maximal symptom-limited intensity is reached. 
Several variables are measured: oxygen pulse which is oxygen 
consumption per heartbeat, maximal oxygen consumption (VO2), 
ventilatory equivalent for carbon dioxide (VE/VCO2), which reflects 
respiratory adaptation to exercise and carbon dioxide (CO2) pro-
duction, heart rate, arterial oxygen saturation (SaO2), and systemic 
arterial tension. It has been showed that VO2 is decreased in PH 
and, as it reflects maximal cardiac output (CO), is a marker of 
impaired cardiac function. Indeed, several studies showed that 
decreased VO2 and increased VE/VCO2 are correlated with cardiac 
function. CPET seems to be a good test to evaluate functional 
capacity, as it is correlated with NYHA class, disease severity, 
clinical worsening, and survival in PAH. It is thus suitable for risk 
stratification. Studies also showed that it is a good test to evaluate 
treatment response. However, CPET is not suitable for most severe 
forms of PH and its realization needs technical expertise (49–52).
Six-Minute walk Test
The six-minute walk test is a submaximal exercise test, frequently 
used in assessment of cardiovascular and pulmonary diseases, 
especially to measure the response to a medical intervention. The 
patient must walk during 6 min, choosing his walking velocity. 
He can use any walking help he usually needs and must not inter-
rupt his medication. Dyspnea and tiredness are evaluated, before 
and after the test, with Borg scale. Even though the patient must 
provide a physical exertion, the test is well tolerated, even for 
severely disabled patients, because they can choose intensity and 
velocity of their walk and can stop at any time. Several contrain-
dications must be taken in consideration, such as unstable angina 
or infarction in the past month. Incidence of complications, such 
as arrhythmias or cardiac arrest, is, for now, unknown, and it is 
thus necessary to perform this test in a place where emergency 
intervention is possible, where rapid administration of drugs and 
oxygen is feasible, and under surveillance of a physician certified 
in cardiopulmonary resuscitation (53).
Several studies demonstrated that it is a good, reproducible test 
to assess patients’ functional capacities. It represents the physi-
cal activity of daily living and thus estimates patients’ capacities 
in a more reliable way than with a self-reporting questionnaire. 
Although physical exertion is not maximal, it has been demon-
strated that the results are correlated with maximal exertion tests 
(49). In PAH, results are strongly correlated with survival, quality 
of life, NYHA class, and hemodynamic parameters. For evaluation 
of treatment benefits, a modification of walk distance superior to 
33  m is considered to be significant, even though the correla-
tion between walk distance and survival remains  controversial. 
However, walk distance reflects the global  cardiovascular, 
pulmonary, and neuromuscular state and is thus not specific to 
the investigated disease. Despite a weaker sensitivity to assess 
treatment response in comparison with other exercise tests, it 
seems that, thanks to its good reproducibility and easy execution, 
it is most suitable to assess evolution of functional capacities and 
cardiovascular state after treatment (2, 5, 49–52, 54).
NYHA Class
New York Heart Association class is a self-assessment of dyspnea 
by the patient. This classification seems to be a good indicator of 
survival in PAH: survival is about 6 years in class I and II, 2.5 years 
in class III, and 6 month in class IV. Some studies showed a good 
correlation between NYHA class and hemodynamic parameters. 
Furthermore, treatment-induced changes can be easily measured 
and are also predictive of survival. Thus, NYHA class could be 
used to adapt treatment (5, 52, 55, 56). However, this classification 
has some limitations, such as important interobservers variability 
and the fact that it is a subjective and self-reported evaluation. 
Moreover, this classification lacks of sensitivity, as it is difficult 
to use it to detect precociously patients with PAH. Detection of 
improvement from a class II to a class I is difficult as well (52).
equations
Eventually, in clinical practice, in order to improve patients’ 
classification according to their prognosis, equations combining 
different clinical, biological, and hemodynamic parameters have 
been developed. As their prognostic value relies on diagnostic and 
therapeutic advances, these equations must be regularly updated. 
The most recent equation results from the REVEAL study per-
formed by Benza et al. It seems to allow a better risk stratification, 
in comparison with variables considered individually (1, 56).
BiOLOGiCAL PARAMeTeRS
N-Terminal of the Prohormone Brain 
Natriuretic Peptide
N-terminal of the prohormone brain natriuretic peptide 
(NT-proBNP) is a peptide released by myocardium when ven-
tricular wall stress is increased by volume overload. It may be 
increased by any left or right cardiac pathology leading to reduced 
cardiac function, and its rate reflects changes of ventricular wall 
stress. In PAH, it has been demonstrated that a higher rate is 
associated with reduced survival (52, 54, 56–58). Indeed, Mauritz 
et al. showed that values above 1.256 pg/ml are associated with a 
worse prognosis. NT-proBNP rates are correlated with hemody-
namic parameters, and negatively correlated with CO and RVEF 
(58– 61). NT-proBNP was also an indicator of a long-term treat-
ment response (61). Park et al. showed that decreased NT-proBNP 
rates after 3 months of treatment with epoprostenol were associ-
ated with a higher survival, particularly if they decreased more 
than 50% from baseline. Thus, it is a sensitive marker of right ven-
tricular dysfunction’s severity and could allow an early assessment 
of treatment response (62). NT-proBNP is exclusively cleared by 
kidneys, and its rates can thus be  overestimated in chronic renal 
impairment, frequently found in PAH. In this case, it seems that 
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the correlation between NT-proBNP rates and hemodynamic 
parameters could be weaker (57, 58).
Diffusion Capacity for Carbon Monoxide
Diffusion capacity for carbon monoxide (DLCO) is used in a large 
number of pulmonary diseases, because it allows non-invasive 
detection of pathological processes inducing perturbations in gas 
exchanges in pulmonary vessels. It is frequently used in systemic 
sclerosis to reveal the presence of PH, as its diffusion is altered by 
arterial wall remodeling. In this pathology, DLCO is also strongly 
correlated with prognosis (63). In other types of PAH, although 
remodeling processes are similar, usefulness of DLCO as a prog-
nostic factor remains controversial. Chandra et al. showed that a 
value inferior to 40% of predicted value is associated with a worse 
prognosis. In another study, a reduced DLCO was associated with 
increased mortality, while values above 80% of predicted were 
associated with increased survival. In contrary, Trip et al. could 
not demonstrate any association between DLCO and prognosis 
or hemodynamic parameters. Reduced DLCO in patients with 
PAH is correlated with smoking, which could mean that reduced 
values reflect rather an underlying pulmonary pathology than a 
severe vascular wall injury. Furthermore, no changes in DLCO 
were found after treatment (1, 56, 64, 65). In clinical practice, 
DLCO is a part of pulmonary function tests, which is mostly used 
in clinical practice in initial assessment of PH to detect connec-
tive tissue disease or interstitial lung diseases. However, the other 
variables of pulmonary function tests have not been included in 
studies and no correlation has been made with prognosis in PAH.
MARKeRS OF CARDiAC FUNCTiON
Cardiac Catheterization
Today, right heart catheterization remains the gold standard for 
the diagnosis of PH. We can measure different hemodynamic 
parameters, such as RAP, PVR, systolic pulmonary pressure 
(PAPs), PAPm, diastolic PAP (PAPd), PWP, cardiac index (CI), 
defined as the ratio between CO and body surface area, or SaO2, 
and venous oxygen saturation (SvO2). As previously mentioned, it 
is used in clinical practice to differentiate pre- and post-capillary 
PH: PWP <  15  mmHg and diastolic pressure gradient (PAPd-
PWP) >7 mmHg suggest pre-capillary PH (3). A lot of studies 
showed a good correlation between prognosis, survival and RAP, 
PAPm, SvO2, CO, and CI. Correlation between CO and PVR is 
consistent with the concept of RV-pulmonary circulation unit 
(1, 2, 44, 52, 56, 66–70). PVR are also strongly correlated with sur-
vival, although association between their decrease after treatment 
and mortality is controversial. However, Sitbon et al. showed that 
a decrease of 30% or more in comparison with baseline values 
is associated with a better prognosis (55, 71). Evolution of CO 
after 16 weeks of treatment is also associated with prognosis, as an 
increase >0.22 l/min is predictive of a better survival (69). Nickel 
et al. demonstrated that CO values superior to 2.5 l/min/m2, and 
SvO2 superior to 65%, at the time of diagnosis, are associated with 
increased survival. Nevertheless, it is mainly their evolution that 
determines the patient’s prognosis: worsening despite satisfying 
baseline values is associated with a higher mortality rate. In 
contrary, improvement despite reduced baseline values predicts 
a lower mortality rate. These results evidence the importance of 
follow-up values (72). During stress, in normal conditions, CO 
and CI increase. Adaptation of CI during stress could allow a 
better stratification of patients, as an increase is predictive of a 
better survival. A positive correlation also exists with six-minute 
walk distance, and a negative correlation with NYHA class. This 
illustrates that, if the heart is capable to increase its output during 
stress, cardiac function is still preserved (73).
However, cardiac catheterization is not suitable for patients’ 
long-term follow-up, as it is quite invasive. Furthermore, values 
are most of the time, obtained at rest and cannot allow evaluation 
of cardiovascular adaptation to stress.
echocardiography
Echocardiography is used as one of the first tool to estimate the 
presence of PH from any group, mainly by measuring PAPs. 
Tricuspid gradient is estimated from peak tricuspid regurgitation 
flow velocity (V). Pressure differential (ΔP) between the RV and 
the right atrium (RA) is obtained by Bernoulli equation: ΔP = 4V2. 
Without pulmonary stenosis, PAPs can then be estimated by 
adding RAP, obtained from the diameter of the vena cava and 
its respiratory variation: a diameter of vena cava >21 mm with 
a collapse <50% with deep inspiration suggests a pathological 
RAP value (>15 mmHg). According to the guidelines, this value 
cannot, itself, make the diagnosis of PAH. Indeed, in about 50% of 
patients, PAPs values estimated with ultrasound do not correspond 
with values obtained at cardiac catheterization. Furthermore, in 
certain situations, Bernoulli equation cannot be applied, because 
pressure gradient is underestimated (3, 74). Diagnosis of PAH 
should be considered, with a degree of probability, in the presence 
of several evocating signs at echocardiography. Even if PAP values 
measured by cardiac catheterization are correlated with survival, 
there is no evidence demonstrating such association with values 
obtained at ultrasound. Global evaluation of right and left cardiac 
chambers, as well as valvular state, helps to establish the prob-
ability of a pre- or post-capillary origin for PH.
The presence of right heart hypertrophy and dilation can be 
assessed with two-dimensional echocardiography (36). As previ-
ously mentioned, hypertrophy, even having deleterious effects, 
is an adaptive mechanism allowing the RV to function despite 
elevated PAP. It is mostly when right ventricular dilation occurs 
that right ventricular dysfunction appears. Indeed, it seems that 
dilation of RV, assessed by echocardiography, is better correlated 
with survival than hypertrophy. Ghio et  al. demonstrated that 
increased ventricular diameter is associated with higher PVR, a 
higher RAP, a lower CI, and a worse survival (36).
RV ejection fraction, which reflects right ventricular function, 
can be measured by echocardiography but remains a visual esti-
mation and is thus unreliable. It is better to use other indicators 
of ventricular function, which also allows an earlier recognition 
of right ventricular dysfunction. We can use the tricuspid annular 
plane systolic excursion (TAPSE). Several studies demonstrated 
that a reduced TAPSE is correlated with a greater right ventricular 
dysfunction and a worse survival (35, 70, 75, 76). Forfia et  al. 
determined a cut-off of 1.8 cm below which is predicted a worse 
prognosis, and greater cardiac remodeling and dysfunction (76). 
FiGURe 2 | Measure of the ei (D1/D2) on a short axis view. D1, 
anteroposterior diameter; D2, septo-lateral diameter (own unpublished data).
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TAPSE only illustrates longitudinal shortening of the RV. It seems 
that, during progression of right ventricular dysfunction, TAPSE 
reaches a limit and does not diminish further, even if right ven-
tricular function and ejection fraction (EF) are still worsening. 
In contrary, transverse systolic shortening, measured by cardiac 
magnetic resonance imagery (cMRI) or echocardiography, 
illustrates right free wall and septal motion and is correlated 
with EF all along the progression of dysfunction. Even though 
free wall deviation also reaches a limit, septal displacement 
progresses with dysfunction. A reduced transverse shortening is 
thus mainly due septal deviation (33, 77). We can combine lon-
gitudinal and transverse shortening in one parameter: the right 
ventricular fractional area change (RVFAC), assessed by cMRI or 
two-dimensional echocardiography. We calculate RVFAC values 
through right ventricular end-diastolic and end-systolic areas like 
this: RVFAC = [(RV end-diastolic area − RV end-systolic area)/
RV end-diastolic area]. RVFAC is correlated with RVEF and its 
evolution through the time and could thus be used as a marker of 
right ventricular function and its evolution. However, its assess-
ment by two-dimensional echocardiography remains difficult 
and less sensitive than by cMRI (77, 78).
Septal position can also be assessed by the eccentricity index 
(EI), described first by Ryan et al., which seems to be a marker 
of both volume and pressure overload in the RV. It is calculated 
as the ratio between anteroposterior and septo-lateral diameters 
of the LV, on a short axis view in two-dimensional echocardi-
ography. (Figure  2) (79). Several studies demonstrated that an 
increased EI, by septal displacement, is correlated with elevated 
RAP and PAP and is associated with a bad prognosis and a 
worse survival. The EI seems to be a very good indicator of right 
ventricular dysfunction and could thus be used as a follow-up 
tool (44, 45, 80). Moreover, Ghio et al. showed that association of 
TAPSE and EI allows detection of patients with global, diastolic 
and systolic dysfunction of the RV (80).
Several studies agree about pericardial effusion to be an excellent 
predictive factor of mortality (35, 44, 66, 70). As it is due to lymphatic 
and venous drainage obstruction in the RA, secondary to elevated 
pressure in this one, it reflects diastolic dysfunction (35, 70).
Tei myocardial index is defined as the sum of isovolumetric 
contraction and relaxation, divided by ejection time. It is a good 
indicator of global right ventricular function and patient’s progno-
sis which is, furthermore, little influenced by ventricle geometry, 
tricuspid regurgitation, and right ventricular filling state. It is 
reproducible and easily calculated, by pulsed or tissular Doppler, 
from pulmonary and tricuspid valves. Increased Tei index is 
associated with a major right ventricular dysfunction (35, 70, 74).
Cardiac Magnetic Resonance imaging
Cardiac magnetic resonance imaging is frequently used in PH to 
assess morphology and function of the RV. It is not the first tool 
used to diagnose PH, even if PH should be considered in presence 
of vascular late gadolinium enhancement and reduced pulmonary 
arterial distensibility (3). Quite the same morphological and func-
tional parameters as echocardiography are studied with cMRI, i.e., 
right ventricular diameter and morphology, RVEF, RVFAC, and 
CO. cMRI can assess more precisely and more easily the com-
plex three-dimensional shape of the RV as well as the RVEF. No 
surrogates to RVEF are needed, and thus it may be preferred to 
echocardiography. Moreover, it has been demonstrated that right 
ventricular diameter and RVEF are correlated with survival (30, 
35, 39). It has also a better reproducibility than echocardiography 
and can be used to assess response to therapies (35, 39, 52). It is 
also possible to measure blood flow in coronary arteries to detect 
ischemic abnormalities, which participate to right ventricular 
dysfunction (52). Right ventricular mass can be easily measured 
and seems to be correlated with right ventricular function and 
survival (35, 39). Magnetic resonance angiography can be done 
simultaneously and can provide information about pulmonary 
vasculature. Indeed, vascular remodeling can be seen by loss of 
peripheral vascular enhancement and ramifications of vascular 
bed. Therefore, MRI allows evaluation of all RV-pulmonary 
circulation unit (39). However, despite major advantages, fewer 
studies have been done about usefulness of cMRI in PH evalua-
tion in comparison with echocardiography, and some correlations 
with other clinical parameters are lacking. cMRI is also expensive 
and less available than echocardiography and can be limited by 
claustrophobia and ferromagnetic devices (35).
Conclusion
In conclusion, in PAH, a lot of markers of right ventricular func-
tion have been developed (Table  1). However, their predictive 
values remain, for most, to be determined. It is recommended 
to use the best studied markers, such as anatomical parameters, 
pericardial effusion, or TAPSE (70, 74).
POSiTRON eMiSSiON TOMOGRAPHY/
COMPUTeD TOMOGRAPHY
18F-FDG Uptake and energetic Metabolism
It is possible to evidence these metabolic abnormalities, in rats 
and in humans, with 18F-fluorodeoxyglucose (18F-FDG) positron 
TABLe 1 | Advantages and downsides of parameters for evaluation of PH.
Parameter Advantages Downsides
CPeT
 – VO2
 – VE/VCO2 CO2
 – Heart rate
 – SaO2
 – Systemic arterial tension
Decreased VO2 reflects limitation of maximal cardiac output, marker of 
impaired cardiac function. Good test to evaluate functional capacity, 
prognosis, and treatment response
Not suitable for most severe forms of PH 
needs technical expertise
6MwT
 – Walking distance
 – Dyspnea
 – SaO2
Well tolerated, even for severely disabled patients. Reproducible test, 
correlated with maximal exertion tests, survival, quality of life, NYHA 
class, and hemodynamic parameters in patients with moderate or 
severe disease
Walk distance reflects the global 
cardiovascular, pulmonary, and 
neuromuscular, not specific to PAH alone
NYHA Good correlation with hemodynamic parameters. Evaluation of 
treatment response, predictive of survival
Important interobservers variability, 
subjective, and self-reported evaluation. 
Lacks of sensitivity
NT-proBNP Higher level associated with reduced survival. Correlated with 
hemodynamic parameters, and negatively correlated with cardiac 
output (CO) and RVEF. Indicator of long-term treatment response
Increased by any left or right cardiac 
pathology, overestimated in chronic renal 
impairment
DLCO Non-invasive detection of perturbations in gas exchanges in pulmonary 
vessels. Strongly correlated with prognosis in systemic sclerosis
Prognostic value controversial in other 
forms of PAH. Not modified by treatment
Cardiac catheterization
 – RAP
 – PVR
 – PAPs
 – PAPm
 – PAPd
 – PWP
 – CI
 – SaO2
 – SvO2
Gold standard for the diagnosis of PH. Used in clinical practice to 
differentiate pre- and post-capillary PH. SvO2 and right filling pressure 
have a good correlation with prognosis and survival
Invasive, not suitable for patients’ long-term 
follow-up
echocardiographic parameters
 – PAPs
 – Global evaluation of cardiac chambers 
and vavlulae
 – RV diameter
 – RVEF
 – RVFAC
 – TAPSE
 – EI
 – Tei myocardial index
Easily available, unexpensive. First tool for screening. Many parameters 
to evaluate global anatomy and function of the RV and LV, as well as 
valvular state. Correlation with right ventricular function and survival
High intra- and interobservers variability, 3D 
evaluation of the whole RV difficult. Many 
parameters remain semi-quantitative. RVEF 
unreliable, surrogate parameters needed
cMRi
 – Right ventricular diameter and 
morphology
 – RVEF
 – RVFAC
 – Cardiac output
 – Blood flow
 – Magnetic resonance angiography
More precise and accurate evaluation of the complex three-
dimensional shape of the RV. No surrogate to RVEF needed. Evaluation 
of all RV-pulmonary circulation unit: vascular remodeling can be seen 
by angiography by loss of peripheral vascular enhancement and 
ramifications of vascular bed. Good reproducibility can be used to 
assess response to therapies
Fewer studies have been done, some 
correlations with other clinical parameters 
are lacking. Expensive and less available 
than echocardiography, limited by 
claustrophobia and ferromagnetic devices
18F-FDG-PeT/CT (SUv) Biomarker of the metabolic shift in the RV and early marker of cardiac 
dysfunction. Correlated with hemodynamic values, NT-proBNP, several 
echocardiographic parameters, and long-term prognosis
Not available in every center. Irradiation. Not 
used in clinical practice yet
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emission tomography/computed tomography (PET/CT), both in 
myocardium and in pulmonary vessels (Figure 3) (25–27, 81). 
We usually describe 18F-FDG uptake by the standard uptake value 
(SUV), an index measured as: SUV = tracer concentration in a 
given place/(injected activity × body mass). In experimental stud-
ies, it has been shown that 18F-FDG uptake in PAH is secondary to 
increased GLUT-1 channels expression and anaerobic glycolysis 
activation (25, 81–83). In the myocardium, increased 18F-FDG 
uptake is also due to a greater cardiac work or myocardial stress, 
which is the strength that the heart must provide to eject a blood 
volume against elevated pulmonary pressure. It can also be due to 
ischemia present in hypertrophy, which can switch the metabo-
lism toward anaerobic glycolysis (81, 84). In contrary, it has 
been demonstrated that increased uptake cannot be explained 
by hypertrophy itself or by increased right ventricular free wall 
thickness (81).
Severity and Prognosis
A higher mortality rate has been observed when free fatty acids 
uptake was reduced in favor of glycolysis. Indeed, Tatebe et al. 
demonstrated that the SUV of the right ventricular free wall is 
correlated with long-term prognosis in patients with PAH, with 
FiGURe 3 | Pictures obtained from a 67-year-old man with PH of mixed origin (COPD, left heart dysfunction). 18F-FDG-PET/CT shows a dilation of the 
RV with an increased and heterogeneous uptake. A hypometabolism of the infero-lateral medial wall is found in the LV (own unpublished data).
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a threshold of 8.3, below which survival is decreased. SUV could 
thus be useful as a biomarker of this metabolic shift and thus, as 
an early marker of cardiac dysfunction (25, 26, 30, 83). It could 
allow a better stratification of patients according to the severity 
of the disease and be used to define best their prognosis. Several 
studies evidenced that 18F-FDG uptake ratio between the RV and 
the LV is correlated with PAP (30). Kluge et al. demonstrated 
that RVEF and Tei index are correlated with uptake ratio, by 
reduced uptake in the LV. This could be explained by decreased 
energetic needs in the LV because of diminished parietal stress 
and pre-load (84). In contrary, other studies also showed the 
same correlation, but explained by increased uptake in the 
RV (82, 85). 18F-FDG uptake is thus correlated not only with 
hemodynamic values but also with NT-proBNP (85). Lundgrin 
et al. showed that the right myocardial SUV is correlated with 
several echocardiographic parameters, such as the right ven-
tricular end-systolic diameter, the EI, and the RFVAC (26). A 
recent study performed by Li et al. confirmed the relationship 
between RV/LV 18F-FDG uptake ratio and cardiac dysfunction, 
as an increased uptake was an independent predictive factor of 
a long-term poor prognosis and mortality. Thus, PET/CT seems 
to have a prognostic value in assessment of right ventricular 
function (86).
Oikawa et al. showed that, in patients responding to treatment 
with epoprostenol, the decrease of right ventricular SUV was 
correlated with changes of PVR, PAPm, and parietal stress of the 
RV (81). 18F-FDG-PET/CT could also be a useful tool to assess 
treatment response.
82Rb-PeT/CT
Studies about left ventricular hypertrophy showed that the PET/
CT with rubidium-82 (82Rb), associated with a stress test and a 
cold pressor test, is a sensitive and non-invasive exam that can 
be used to evidence the presence of endothelial dysfunction and 
perfusion abnormalities in coronary arteries (87–90). However, it 
has never been used in the context of PH. Endothelial dysfunction 
has been demonstrated to be a part of the pathogenesis of PAH in 
pulmonary arteries, but only a few studies evidenced its presence 
in the systemic and coronary circulations (91–93). In the future, 
82Rb-PET/CT could be used to study perfusion abnormalities of 
the RV and to better understand right ventricular dysfunction.
CONCLUSiON
Despite major discoveries have been made these past years con-
cerning the mechanisms underlying the development of PAH, 
mortality rates remain high and available treatments cannot 
reverse vessels wall injuries. Other treatments targeted on the 
pathogenesis are being studied. It will be necessary, in the com-
ing years, to develop their clinical utilization in order to improve 
prognosis of patients with PAH.
Right ventricular dysfunction, mostly due to right ventricular 
dilation, is the main cause of death. More and more markers of 
right ventricular function have been studied, but clinical practices 
disagree concerning parameters that should be used. Currently, 
hemodynamic values, obtained by cardiac catheterization, remain 
decisive to establish, not only the diagnosis but also the prognosis, 
and to follow the evolution of the disease. It is recommended to 
associate biological, hemodynamic, and imagery parameters. 
However, it will be necessary to standardize patients’ care and 
to determine prognostic values of those parameters, in order to 
optimize follow-up and allow a better monitoring of right heart 
function.
Finally, nuclear cardiac imaging has been recently used to 
assess cardiac repercussions of PAH. Number of evidences 
demonstrated that metabolic abnormalities are present in the 
right myocardium and that they can be observed by 18F-FDG-
PET/CT. Their participation in right heart dysfunction has also 
been highlighted. Even though these first results showed a good 
sensitivity to assess ventricular metabolism and function, further 
studies are necessary to confirm its usefulness and its adequacy 
for clinical patients’ follow-up.
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